SCOPUS 정보 검색 플랫폼

American Journal of Public Health

Volumn 102, Issue 9, 2012, Pages 1655-1659

A layered approach to raising public awareness of Macular Degeneration in Australia

(2) Heraghty, Julie a Cummins, Robert a

a Australian Macular Degeneration Foundation (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ARTICLE; ATTITUDE TO HEALTH; AUSTRALIA; HEALTH EDUCATION; HEALTH PROMOTION; HUMAN; INFORMATION PROCESSING; METHODOLOGY; MIDDLE AGED; RETINA MACULA DEGENERATION;

ADOLESCENT; AUSTRALIA; DATA COLLECTION; HEALTH EDUCATION; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HEALTH PROMOTION; HUMANS; MACULAR DEGENERATION; MIDDLE AGED;

EID: 84865681905 PISSN: 00900036 EISSN: 15410048 Source Type: Journal
DOI: 10.2105/AJPH.2012.300657 Document Type: Review

Times cited : (9)

References (6)

1
- 84865696424
- Eyes on the future: A clear outlook on age-related macular degeneration
- Deloitte Access Economics, October, Accessed November 1, 2011
- Deloitte Access Economics. Eyes on the future: a clear outlook on age-related macular degeneration. Report prepared for the Macular Degeneration Foundation. October 2011. Available at: http://www.mdfoundation. com.au/LatestNews/MDFoundationDeloitteAccessEconomicsReport2011.pdf. Accessed November 1, 2011.
- (2011) Report Prepared for the Macular Degeneration Foundation

2
- 57949094834
- Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study
- Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, Ianchulev T. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology. 2009;116(1):57-65.
- (2009) Ophthalmology , vol.116 , Issue.1 , pp. 57-65
- Brown, D.M.¹ Michels, M.² Kaiser, P.K.³ Heier, J.S.⁴ Sy, J.P.⁵ Ianchulev, T.⁶

3
- 33749445317
- Ranibizumab for neovascular age-related macular degeneration
- DOI 10.1056/NEJMoa054481
- Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular agerelated macular degeneration. N Engl J Med. 2006;355(14):1419-1431. (Pubitemid 44511557)
- (2006) New England Journal of Medicine , vol.355 , Issue.14 , pp. 1419-1431
- Rosenfeld, P.J.¹ Brown, D.M.² Heier, J.S.³ Boyer, D.S.⁴ Kaiser, P.K.⁵ Chung, C.Y.⁶ Kim, R.Y.⁷

4
- 21044453724
- A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration
- DOI 10.1073/pnas.0501536102
- Hageman GS, Anderson DH, Johnson LV, et al. A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration. Proc Natl Acad Sci U S A. 2005;102(20):7227- 7232. (Pubitemid 40696361)
- (2005) Proceedings of the National Academy of Sciences of the United States of America , vol.102 , Issue.20 , pp. 7227-7232
- Hageman, G.S.¹ Anderson, D.H.² Johnson, L.V.³ Hancox, L.S.⁴ Taiber, A.J.⁵ Hardisty, L.I.⁶ Hageman, J.L.⁷ Stockman, H.A.⁸ Borchardt, J.D.⁹ Gehrs, K.M.¹⁰ Smith, R.J.H.¹¹ Silvestri, G.¹² Russell, S.R.¹³ Klaver, C.C.W.¹⁴ Barbazetto, I.¹⁵ Chang, S.¹⁶ Yannuzzi, L.A.¹⁷ Barile, G.R.¹⁸ Merriam, J.C.¹⁹ Smith, R.T.²⁰ more..

5
- 74549137478
- Ranibizumab (Lucentis) in neovascular age-related macular degeneration: Evidence from clinical trials
- Mitchell P, Korobelnik JF, Lanzetta P, et al. Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials. Br J Ophthalmol. 2010;94(1):2-13.
- (2010) Br J Ophthalmol. , vol.94 , Issue.1 , pp. 2-13
- Mitchell, P.¹ Korobelnik, J.F.² Lanzetta, P.³

6
- 77955348492
- Medicare Australia, Accessed November 1, 2011
- Medicare Australia. Medicare Item Reports (items 10900 to 10918). Available at: https://www.medicareaustralia. gov. au/statistics/mbs-item.shtml. Accessed November 1, 2011.
- Medicare Item Reports (items 10900 to 10918)

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.